Interleukin-1 receptor antagonist gene polymorphism increases susceptibility to septic shock in children with acute lymphoblastic leukemia

Pediatric Infectious Disease Journal

Volumn 32, Issue 2, 2013, Pages 136-139

  Zapata Tarrés, Marta ^a   Arredondo García, Jose Luis ^b   Rivera Luna, Roberto ^b   Klünder Klünder, Miguel ^a   Mancilla Ramírez, Javier ^a   Sánchez Urbina, Rocío ^a   Vázquez Cruz, Margarita Yolanda ^b   Juárez Villegas, Luis Enrique ^a   Palomo Colli, Miguel Angel ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

children; acute lymphoblastic leukemia; febrile neutropenia; interleukin 1 receptor antagonist gene polymorphism; septic shock

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CEFEPIME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MEROPENEM; VANCOMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADOLESCENT; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LOGISTIC MODELS; MALE; NEUTROPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SHOCK, SEPTIC; STATISTICS, NONPARAMETRIC;

EID: 84873057121     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827566dd     Document Type: Article

References (26)

1. Ross JA, Johnson KJ, Spector LG, et al. Epidemiology of acute childhood leukemia. In: Reaman GH, Smith FO, Eds. Childhood Leukemia. Berlin, Germany: springer; 2011:3-26.
2. Pérez-saldivar ML, Fajardo-Gutiérrez A, Bernáldez-ríos R, et al. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer. 2011;11:355.
3. Pui CH, Campana D, Evans We. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol. 2001;2:597-607.
4. Margolin JF, Rabin KR, Steuber C P, et al. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, Eds. Principles and Practice of Pediatric Oncology. philadelphia, pA: Lippincott Williams & Wilkins; 2010:518-565.
5. Koh AY, Pizzo PA. Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG, Eds. Principles and Practice of Pediatric Oncology. philadelphia, pA: Lippincott Williams & Wilkins; 2010:1190-1243.
6. Hughes WT, Armstrong D, Bodey G P, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases society of America. Clin Infect Dis. 1997;25:551-573.
7. Pound CM, Johnston DL, Armstrong R, et al. the morbidity and mortality of pediatric oncology patients presenting to the intensive care unit with septic shock. Pediatr Blood Cancer. 2008;51:584-588.
8. Castellheim A, Brekke OL, Espevik T, et al. Innate immune responses to danger signals in systemic infammatory response syndrome and sepsis. Scand J Immunol. 2009;69:479-491.
9. Pizzo pA. Fever in immunocompromised patients. N Engl J Med. 1999;341:893-900.
10. Schindler R, Mancilla J, Endres S, et al. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (tNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and tNF. Blood. 1990;75:40-47.
11. Rosenwasser LJ. Biologic activities of IL-1 and its role in human disease. J Allergy Clin Immunol. 1998;102:344-350.
12. Bagby GC Jr. Interleukin-1 and hematopoiesis. Blood Rev. 1989;3:152-161.
13. Langabeer SE, Linch DC. IL-1 receptor antagonist gene polymorphism in patients with secondary acute myeloid leukaemia. Cytokines Cell Mol Ther. 1998;4:7-9.
14. Demeter J, Messer G, Rämisch S, et al. polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther. 1996;2:239-242.
15. Hulkkonen J, Vilpo J, Vilpo L, et al. Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica. 2000;85:600-606.
16. Mancilla J, García P, Dinarello CA. the interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun. 1993;61:926-932.
17. Mancilla Ramírez JAG, Vannier E, Dinarello CA. Interleucina-1, inter-leucina-6 y factor de necrosis tumoral en sepsis neonatal. Perinatol Reprod Hum. 1996; 10:230-237.
18. Granowitz E V, Clark BD, Mancilla J, et al. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleu-kin-1 receptor. J Biol Chem. 1991;266:14147-14150.
19. Tarlow JK, Blakemore AI, Lennard A, et al. polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993;91:403-404.
20. Danis VA, Millington M, Hyland VJ, et al. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1ra) gene polymorphism. Clin Exp Immunol. 1995;99:303-310.
21. Fang XM, Schröder S, Hoeft A, et al. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med. 1999;27:1330-1334.
22. Arnalich F, López-Maderuelo D, Codoceo R, et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol. 2002;127:331-336.
23. Pui CH, Relling M V, Sandlund JT, et al. rationale and design of total therapy study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol. 2004;83(suppl 1):s124-s126.
24. Bone RC, Balk RA, Cerra FB, et al.; ACCp/sCCM Consensus Conference Committee. Defnitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. the ACCp/sCCM Consensus Conference Committee. American College of Chest physicians/society of Critical Care Medicine. 1992. Chest. 2009;136(suppl 5):e28.
25. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1ra) plasma levels are co-ordinately regulated by both IL-1ra and IL-1beta genes. Eur J Immunol. 1998;28:2598-2602.
26. Hulkkonen J. Infamatory Cytokines and Cytokine Gene Polymorphisms in Chronic Lymphocytic Leukaemia, in Primary Sjogren Syndrome and in Healthy Subjects. Kalevantie, Finland: tampere University press; 2002:45.